EMA Adopts a New Pharmaceutical Form of Selumetinib By Ogkologos - December 16, 2025 44 0 Facebook Twitter Google+ Pinterest WhatsApp It is associated with an extension to the existing indication Source RELATED ARTICLESMORE FROM AUTHOR Noninferiority of OS with 3 Months Compared to 6 Months of Adjuvant Chemotherapy for Patients with High-Risk Stage III Colorectal Cancer Patient Guide on Bone Health in Cancer Now Available Also in French Lung Cancer Death Rates Among Women in Europe Are Finally Levelling Off MOST POPULAR Cancer in My Community: Caring for the Whole Patient in Brazil December 7, 2023 ETV6 Protein Could Be an Important Target for Ewing Sarcoma Treatment March 7, 2023 FDA Approves Avapritinib for Advanced Systemic Mastocytosis June 17, 2021 Childhood cancer survivors at greater risk of ill health November 22, 2021 Load more HOT NEWS Potential of NOTCH1 Mutation to Predict Anti-PD1 Treatment Outcomes in Patients... Findings support de-escalated radiotherapy after surgery in HPV-associated oropharyngeal squamous cell... FDA Approves Mitomycin Intravesical Solution for Recurrent Low Grade Intermediate Risk... Significant OS Benefit with Glofitamab plus GemOx in Transplant-Ineligible Patients with...
